Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is a biopharmaceutical royalty company that frequently announces transactions, portfolio updates and financial results, making its news flow particularly relevant for investors following royalty-based business models in healthcare. Founded in 1996, the company describes itself as the largest buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry, with a portfolio of royalties on more than 35 commercial products and numerous development-stage therapies.
News about Royalty Pharma often centers on new royalty acquisitions and funding agreements. Recent press releases have described transactions such as acquiring remaining royalty interests in Roche’s Evrysdi, purchasing a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences, and securing royalty interests in Nuvalent’s neladalkib and zidesamtinib. The company also reports synthetic royalty funding agreements, including a deal with Denali Therapeutics based on future net sales of tividenofusp alfa and a funding agreement with Teva for the anti-IL-15 antibody TEV-‘408 for vitiligo and celiac disease.
Royalty Pharma’s news feed additionally includes quarterly financial results, Portfolio Receipts updates, capital deployment figures, debt offerings, dividend declarations and participation in investor conferences. The company highlights clinical and regulatory milestones across its royalty portfolio, such as FDA approvals, Phase 3 trial initiations and pivotal data readouts for therapies like daraxonrasib, litifilimab, pelacarsen and other late-stage candidates.
Investors and observers who follow RPRX news can use these updates to track how the royalty portfolio is evolving, which therapeutic areas are gaining exposure, and how capital is being allocated across approved and investigational products. Regular news also provides insight into Royalty Pharma’s views on the royalty funding market, its use of non-GAAP liquidity measures, and its approach to shareholder returns through dividends and share repurchases.
Ionis Pharmaceuticals has announced a significant royalty agreement with Royalty Pharma, involving an upfront payment of $500 million and potential milestones of up to $625 million. This deal allows Royalty Pharma to acquire an interest in Ionis' royalties from SPINRAZA and pelacarsen, while Ionis retains the majority of royalties and milestone payments from Novartis. The investment aims to bolster Ionis' late-stage programs and innovative genetic medicines pipeline, highlighting confidence in the commercial potential of both therapies.
Royalty Pharma plc (Nasdaq: RPRX) has declared a quarterly dividend of $0.20 per Class A share for the first quarter of 2023, marking a 5.3% increase from the previous quarter. The dividend will be paid on March 15, 2023, to shareholders of record as of February 16, 2023. CEO Pablo Legorreta emphasized the company's commitment to returning capital to shareholders while maintaining financial flexibility for future innovations, noting strong demand for capital in the biopharma sector.
Royalty Pharma, listed on Nasdaq as RPRX, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. ET. The presentation can be accessed via the company's Events page and will be archived for at least 30 days. Founded in 1996, Royalty Pharma is a leader in biopharmaceutical royalties, funding innovation through collaborations with various biopharmaceutical entities. Its portfolio includes royalties from over 35 commercial products.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a $25 million milestone payment from Amgen (NASDAQ: AMGN) triggered by the enrollment of the first subject in Amgen's Phase 3 trial of olpasiran. Arrowhead is also in line to receive up to $535 million in additional milestone payments from Amgen and Royalty Pharma (NASDAQ: RPRX). The olpasiran therapy targets lipoprotein(a) to reduce cardiovascular disease risk. This milestone represents significant progress for Arrowhead, being the second TRiM-enabled candidate to enter Phase 3 trials, with more projected to follow in the coming year.
Royalty Pharma plc (Nasdaq: RPRX) has announced key promotions within its senior leadership team effective January 1, 2023. Sara Klymkowsky and Brienne Kugler are promoted to Senior Vice President, Research & Investments, recognized for their significant contributions to major transactions since they joined the company in 2012 and 2014, respectively. Alessandra Sassun is appointed Senior Vice President, Head of Human Capital, bringing experience in human resources. CEO Pablo Legorreta expressed confidence that this strengthened leadership will enhance Royalty Pharma's mission in life sciences innovation and stakeholder value.
Royalty Pharma plc (Nasdaq: RPRX) is set to join the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 30, 2022, at 10:30 a.m. ET. Investors can access the live webcast via Royalty Pharma’s “Events” page, where it will be archived for at least 30 days.
Royalty Pharma, founded in 1996, specializes in acquiring biopharmaceutical royalties. The company collaborates with various innovators across the biopharmaceutical sector and currently holds royalties for over 35 commercial products, enhancing the funding of innovation within the industry.
Royalty Pharma (Nasdaq: RPRX) has acquired a royalty interest in Amgen's olpasiran from Arrowhead Pharmaceuticals for $250 million in cash, with potential additional payments up to $160 million based on certain milestones. Olpasiran, developed to reduce lipoprotein(a) levels associated with cardiovascular diseases, has shown promise in Phase 2 studies. Arrowhead retains rights to $400 million in milestone payments from Amgen. This acquisition reinforces Royalty Pharma's strategy to invest in innovative therapies targeting unmet medical needs.
Arrowhead Pharmaceuticals has announced that Royalty Pharma has acquired a royalty interest in Amgen's olpasiran for $250 million upfront, plus up to $160 million in additional payments based on milestones. Olpasiran, developed for cardiovascular disease treatment, is approaching Phase 3 trials. Arrowhead retains rights to $400 million in milestone payments related to Amgen's development of olpasiran. This agreement reinforces the potential of olpasiran and supports Arrowhead's investment in its RNAi therapeutic pipeline.
Royalty Pharma (RPRX) reported Q3 2022 results showing net cash from operations of $539 million, up 15% year-over-year. Adjusted Cash Receipts increased 2% to $597 million. The company raised its full-year guidance for Adjusted Cash Receipts to between $2,750 million and $2,800 million, reflecting positive performance driven by royalty acquisitions and existing product sales, particularly in the cystic fibrosis and oncology sectors. Notably, transactions year-to-date have reached $3.0 billion, highlighting ongoing growth and market demand.
Royalty Pharma plc (RPRX) will announce its third quarter 2022 financial results on November 8, 2022, before U.S. markets open. A conference call will follow at 8:00 a.m. Eastern Time, accessible via the company's website. Royalty Pharma specializes in acquiring biopharmaceutical royalties and funding innovation in the sector, holding royalties on over 35 commercial products. These include notable therapies like Vertex's Trikafta and Biogen's Tysabri. For further details, visit the company's investors page.
FAQ
What is the current stock price of Royalty Pharma Plc (RPRX)?
What is the market cap of Royalty Pharma Plc (RPRX)?
